Showing results (4461-4470 of 45,233) with videos related to
Sort By:
Pageof 4,524
Cancer Research|January 20, 2004
Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cellsJingxia Li, Gerard Davidson, Yi Huang, et al.Cancer Research|January 20, 2004
Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signalingJing Yi, Jie Yang, Rong He, et al.Cancer Research|January 20, 2004
Angiogenic acceleration of Neu induced mammary tumor progression and metastasisRobert G Oshima, Jacqueline Lesperance, Varinia Munoz, et al.Cancer Research|January 20, 2004
Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor geneThierry Massfelder, Herve Lang, Eric Schordan, et al.Cancer Research|January 20, 2004
Glycine-extended gastrin promotes the growth of lung cancerTheodore J Koh, John K Field, Andrea Varro, et al.Cancer Research|January 20, 2004
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathwayFelix Herrmann, Hans-Anton Lehr, Ingo Drexler, et al.Cancer Research|January 20, 2004
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growthAda Girnita, Leonard Girnita, Fabrizio del Prete, et al.Cancer Research|January 20, 2004
Significant differences in the effects of magnetic field exposure on 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in two substrains of Sprague-Dawley ratsMaren Fedrowitz, Kenji Kamino, Wolfgang LöscherCancer Research|January 20, 2004
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cellsAnne Boulay, Sabine Zumstein-Mecker, Christine Stephan, et al.Cancer Research|January 20, 2004
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculatureThomas W Davis, Janet M O'Neal, Mark D Pagel, et al.Pageof 4,524